logo
Plus   Neg
Share
Email

Novo Nordisk: Tresiba Shows Lower Rate Of Hypoglycaemia Than Lantus

Novo Nordisk (NVO) announced the headline results from SWITCH 1, the second of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, comparing the safety and efficacy of Tresiba (insulin degludec) and Lantus (insulin glargine U100).

The company expects to initiate filing of the data from the SWITCH trials with regulatory authorities in third quarter of 2016 with the aim of updating the label for Tresiba.

The company noted that the trial met the primary end-point by demonstrating non-inferiority in the rate of severe or blood glucose confirmed symptomatic hypoglycemia of Tresiba compared to insulin glargine.

Novo Nordisk said Tresiba appeared to have a safe and well-tolerated profile.
Adverse events were comparable between the two treatment arms.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said, " We are very excited about these trial results, which document that Tresiba also in people with type 1 diabetes significantly reduces the risk of
hypoglycaemia compared to insulin glargine"

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT